NEXT GENERATION ANTI-
INFECTIVES.

Pipeline

Bacteremia

Influenza


Pipeline

We plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. Our most advanced product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia and CF-404, a cocktail of monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza.



Bacteremia (S. aureus)

CF-301 and CF-302 are bacteriophage lysins with potent activity against Staph aureus infections.

Staph infections occur in both hospital and community settings, and in the U.S. there are approximately 120,000 cases annually of Staph bacteremia (a blood borne infection), which causes approximately 30,000. Of further concern, drug-resistant strains of Staph are now evolving additional resistance against standard-of-care (SOC) antibiotics, which may ultimately result in increased number of cases and mortality from Staph bacteremia.

CF-301 is a bacteriophage lysin that has the potential to be a first-in-class treatment for Staph bacteremia. CF-301 has specific and rapid bactericidal activity against Staph. Combinations of CF-301 with vancomycin or daptomycin increased survival significantly in animal models of diseasewhen compared to treatment with antibiotics alone.

CF-301 and CF-302 target conserved regions of the cell wall that are vital to bacteria, thus making resistance less likely to develop. When used in combination with SOC antibiotics, the result is a novel combination therapy that has the potential to combat the high unmet clinical need of S. aureus infections.

Influenza

CF-404 is a cocktail of three monoclonal antibodies (CF-401, which targets Type A; Group 1 influenza; CF-402, which targets Type A; Group 2 influenza; and CF-403, which targets Type B influenza). With the breadth of reactivity of its components, CF-404 is a universal therapeutic cocktail for the treatment of life-threatening seasonal and pandemic varieties of influenza.

Even with the influenza vaccine, with efficacy that varies year to year, influenza infections still result in over 200,000 hospitalizations and up to 40,000 deaths annually in the U.S. alone. Globally, on an annual basis 20% of children and 5% of adults develop symptomatic influenza.

As a result of genetic drift and genetic shift, mutations in influenza occur each year as it circulates through the population. These mutations may result in drug-resistance, which is a frequent event with influenza, and in avoidance of the vaccine, which causes the need for annual reformulation. In addition, influenza has multiple chromosomes, and the virus can grow in a variety of species (e.g. human, swine and bird) and may result in novel strains of influenza entering into circulation (i.e., swine flu or 2009 H1N1). These new viruses have the potential to cause worldwide pandemics.

The antibodies being developed at ContraFect react with conserved regions on hemagglutinin, the principal protein on the surface of influenza. Utilizing a cocktail of three antibodies that bind to conserved regions on all strains of influenza, we have developed CF-404, which is a therapeutic antibody cocktail that can be used without reformulation. Moreover, as a therapeutic, CF-404 makes it unlikely that drug resistance will occur and provides immediate therapeutic benefits, which is unachievable by vaccination.